Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059375
Filing Date
2025-04-28
Accepted
2025-04-28 16:46:41
Documents
6
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A lxeo-def_14a-2025_proxy.htm DEF 14A 916450
2 GRAPHIC img209845168_0.jpg GRAPHIC 249964
3 GRAPHIC img209845168_1.jpg GRAPHIC 9749
4 GRAPHIC img209845168_2.jpg GRAPHIC 3730
5 GRAPHIC img209845168_3.jpg GRAPHIC 416173
6 GRAPHIC img209845168_4.jpg GRAPHIC 188112
  Complete submission text file 0000950170-25-059375.txt   2112248
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41855 | Film No.: 25881207
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)